We are monitoring the impact of COVID-19 on Europe Injectable Drug Delivery Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 2017
Share on
Share on

Europe Injectable Drug Delivery Market Research Report – Segmented By Device Type, Formulation, Therapeutic Use, End User, & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis on Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 2017
Pages: 145

Europe Injectable Drug Delivery Market Size (2021 to 2026)

The size of the European Injectable Drug Delivery Market was calculated at USD 1256.64 million in 2021. It is further estimated to be growing at a CAGR of 11.90%, to reach USD 2204.75 million by 2026.

A few of the key factors driving the growth of the injectable drug delivery market in the European region are the increasing use of biologics, high prevalence of chronic diseases, and presence of a large population increased expenditure on healthcare, and constant research and development. In addition, an injectable drug delivery system has benefits over other drug delivery techniques such as convenience, ease of use, quick delivery, increased drugs absorption rate and pain reduction, and easy availability. An article published by PHARMAC indicates, global spending on all drugs increased by 25%. According to the Guttmacher Institute, in 2015, over 2,650,000 women used injectables for contraception. Noristerat Injection is a prescription reversible contraceptive method common in the UK and other parts of Europe. According to the European Commission report, around 555,000 premature deaths in the European Union were attributed to chronic diseases, including heart attacks, strokes, diabetes, and cancer.

Biologics currently represent around 72% of the ten best-selling drugs in the world. Since biosimilar and antibiotics are primarily administered by injection, the biologics market is expected to drive the European injectable drug delivery growth in the coming years. Favorable reimbursement policies also drive the market, a higher incidence of cancer, HIV, and diabetes, an increase in vaccinations, a growing number of hospitals and other healthcare facilities, and greater patient adherence to injectables.

However, there have been several products recalls in the market due to strict regulatory policies. If a product is recalled, the process of recovering and replacing the defective product can cause a business or manufacturer to incur significant losses associated with the replacement and repair of faulty products. This is expected to reflect a negative impact on the market and result in failure.

One of the main factors restraining the market growth is the high number of needle stick injuries. The European Biosafety Network estimated that in 2010 there were over a million needlestick injuries per year in Europe. Furthermore, the world Health Organization (WHO) has estimated that these numbers are expected to increase by at least 25% for upcoming years. Again, according to the European Center for Disease Prevention and Control, people who inject drugs or abuse drugs are at increased risk of HIV infection in Europe. In 2015, an HIV prevalence of 7% or more was observed among 19 European countries, including France, Switzerland, Spain, and Italy. Hence, safety related to injectable drug delivery is an important issue that could slow the market's growth.

Complications with needlestick injury can cause serious health consequences, such as damage and blockage of blood vessels, nerve damage, inflammation, phlebitis, edema, allergic reaction, risk of embolization, and infection. Hence, with the increase in side effects and high-risk rates by the needles, the patients are reluctant to use the injections, which is hampering the growth of the European injectable drug delivery market.

This research report on the European injectable drug delivery market has been segmented and sub-segmented into the following categories:

By Device Type: 

  • Self-Injection Devices
  • Conventional Devices

By Formulation: 

  • Conventional Drug Delivery
  • Novel Drug Delivery

By Therapeutic use: 

  • Autoimmune Disorders
  • Hormonal Disorders
  • Oncology

By End User: 

  • Hospitals
  • Homecare Settings
  • Research Institutes
  • Clinical Laboratories

By Country: 

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

European countries such as France and Italy are anticipated to gather significant CAGR over the forecast period. The market growth in these regions can be attributed to the advancing pharmaceutical sector with growing healthcare needs, high healthcare expenditure, and improving economies. According to the European Federation of Pharmaceutical Industries and Associations, around thirty pharmaceutical organizations are satisfied with drug administration technologies in France. As a result, key market players are focusing on developing better and improved drug delivery technologies to meet the increased demand for generics, which is projected to drive market growth.

The growth of the injectable drug market in the United Kingdom and Germany will have a good market share in the European market. Market growth can be attributed to the new injectable drugs, high incidence of chronic diseases such as cancer, improving healthcare awareness, and growing investments focused on advancing technologies.

KEY MARKET PLAYERS:

Companies playing a prominent role in the European Injectable drug delivery market profiled in the report are Antares Pharmaceuticals Ltd, Baxter International, Becton Dickinson Company, Elcam Medical, Eli Lily and Company, Unilife Corporation, and West Pharmaceutical Inc.

1.Introduction           

                1.1 Market Definition              

                1.2 Study Deliverables            

                1.3 Base Currency, Base Year and Forecast Periods   

                1.4 General Study Assumptions          

2. Research Methodology                    

                2.1 Introduction        

                2.2 Research Phases                

    2.2.1 Secondary Research     

    2.2.2 Primary Research 

    2.2.3 Econometric Modelling

    2.2.4 Expert Validation  

                2.3 Analysis Design  

                2.4 Study Timeline   

3. Overview                

                3.1 Executive Summary          

                3.2 Key Inferences  

                3.3 Epidemology       

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)             

                4.1 Market Drivers   

                4.2 Market Restraints              

                4.3 Key Challenges  

                4.4 Current Opportunities in the Market       

5. Market Segmentation                       

                5.1 Device Type        

    5.1.1 Introduction     

    5.1.2 Self-injection Devices   

    5.1.3  Conventional Devices  

    5.1.4  Y-o-Y Growth Analysis, By Device Type

    5.1.5  Market Attractiveness Analysis, By Device Type    

    5.1.6  Market Share Analysis, By Device Type     

                5.2 Formulation        

    5.2.1 Introduction     

    5.2.2 Conventional Drug Delivery       

    5.2.3  Novel Drug Delivery     

    5.2.4 Y-o-Y Growth Analysis, By Formulation 

    5.2.5 Market Attractiveness Analysis, By Formulation     

    5.2.6 Market Share Analysis, By Formulation

                5.3 Therapeutic Use

    5.3.1 Introduction     

    5.3.2 Autoimmune Disorders     

    5.3.3 Hormonal Disorders      

    5.3.4 Oncology 

    5.3.5 Y-o-Y Growth Analysis, By Therapeutic Use        

    5.3.6  Market Attractiveness Analysis, By Therapeutic Use     

    5.3.7  Market Share Analysis, By Therapeutic Use       

                5.4 End-user

    5.4.1 Introduction     

    5.4.2 Hospitals  

    5.4.3 Homecare Settings        

    5.4.4 Research Institutes       

    5.4.5 Clinical Laboratories      

    5.4.6 Other  

    5.4.7 Y-o-Y Growth Analysis, By End-user

    5.4.8  Market Attractiveness Analysis, By End-user

    5.4.9  Market Share Analysis, By End-user

6. Geographical Analysis                       

                6.1 Introduction        

    6.1.1 Regional Trends    

    6.1.2 Impact Analysis     

    6.1.3 Y-o-Y Growth Analysis  

6.1.3.1 By Geographical Area         

6.1.3.2 By Device Type      

6.1.3.3 By Formulation      

6.1.3.4 By Therapeutic Use             

6.1.3.5 By End-user

    6.1.4  Market Attractiveness Analysis     

6.1.4.1 By Geographical Area         

6.1.4.2 By Device Type      

6.1.4.3 By Formulation      

6.1.4.4 By Therapeutic Use             

6.1.4.5 By End-user

    6.1.5  Market Share Analysis

6.1.5.1 By Geographical Area         

6.1.5.2 By Device Type      

6.1.5.3 By Formulation      

6.1.5.4 By Therapeutic Use             

6.1.5.5 By End-user

                6.2 U.K           

                6.3 Spain      

                6.4 Germany               

                6.5 Italy        

                6.6 France   

7.Strategic Analysis                 

                7.1 PESTLE analysis  

    7.1.1 Political     

    7.1.2 Economic 

    7.1.3 Social   

    7.1.4 Technological   

    7.1.5 Legal    

    7.1.6 Environmental 

                7.2 Porter’s Five analysis       

    7.2.1 Bargaining Power of Suppliers  

    7.2.2 Bargaining Power of Consumers    

    7.2.3 Threat of New Entrants     

    7.2.4 Threat of Substitute Products and Services        

    7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                  

                8.1 Alkermes Inc.     

    8.1.1 Overview 

    8.1.2 Product Analysis   

    8.1.3 Financial analysis  

    8.1.4 Recent Developments 

    8.1.5 SWOT analysis 

    8.1.6 Analyst View    

                8.2 Bend Research   

                8.3 BIND Biosciences Inc.      

                8.4 Endocyte               

                8.5 Genentech Inc.  

                8.6 MicroCHIPS Inc. 

                8.7 Pearl Therapeutics Inc.   

                8.8 Polymer Factory

                8.9 Presage Bioscience           

                8.10  QLT Inc.               

                8.11 UCB Group.       

9.Competitive Landscape                     

                9.1 Market share analysis     

                9.2 Merger and Acquisition Analysis

                9.3 Agreements, collaborations and Joint Ventures

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities              

Appendix               

                a) List of Tables                

                b) List of Figures 

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • The segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Injectable Drug Delivery Market, By Device Type, From 2021 to 2026 (USD Million)
  2. Europe Self-injection Devices Market, By Region, From 2021 to 2026 (USD Million)
  3. Europe Conventional Devices Market, By Region, From 2021 to 2026 (USD Million)
  4. Europe Injectable Drug Delivery Market, By Formulation, From 2021 to 2026 (USD Million)
  5. Europe Conventional Drug Delivery Market, By Region, From 2021 to 2026 (USD Million)
  6. Europe Novel Drug Delivery Market, By Region, From 2021 to 2026 (USD Million)
  7. Europe Injectable Drug Delivery Market, By Therapeutic Use, From 2021 to 2026 (USD Million)
  8. Europe Autoimmune Disorders Market, By Region, From 2021 to 2026 (USD Million)
  9. Europe Hormonal Disorders Market, By Region, From 2021 to 2026 (USD Million)
  10. Europe Oncology Market, By Region, From 2021 to 2026 (USD Million)
  11. Europe Injectable Drug Delivery Market, By End-user, From 2021 to 2026 (USD Million)
  12. Europe Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  13. Europe Homecare Settings Market, By Region, From 2021 to 2026 (USD Million)
  14. Europe Research Institutes Market, By Region, From 2021 to 2026 (USD Million)
  15. Europe Clinical Laboratories Market, By Region, From 2021 to 2026 (USD Million)
  16. U.K. Injectable Drug Delivery Market, By Device Type , From 2021 to 2026 (USD Million)
  17. U.K. Injectable Drug Delivery Market, By Formulation, From 2021 to 2026 (USD Million)
  18. U.K. Injectable Drug Delivery Market, By Therapeutic Use, From 2021 to 2026 (USD Million)
  19. U.K. Injectable Drug Delivery Market, By End-user, From 2021 to 2026 (USD Million)
  20. Germany Injectable Drug Delivery Market, By Device Type , From 2021 to 2026 (USD Million)
  21. Germany Injectable Drug Delivery Market, By Formulation, From 2021 to 2026 (USD Million)
  22. Germany Injectable Drug Delivery Market, By Therapeutic Use, From 2021 to 2026 (USD Million)
  23. Germany Injectable Drug Delivery Market, By End-user, From 2021 to 2026 (USD Million)
  24. France Injectable Drug Delivery Market, By Device Type , From 2021 to 2026 (USD Million)
  25. France Injectable Drug Delivery Market, By Formulation, From 2021 to 2026 (USD Million)
  26. France Injectable Drug Delivery Market, By Therapeutic Use, From 2021 to 2026 (USD Million)
  27. France Injectable Drug Delivery Market, By End-user, From 2021 to 2026 (USD Million)
  28. Italy Injectable Drug Delivery Market, By Device Type , From 2021 to 2026 (USD Million)
  29. Italy Injectable Drug Delivery Market, By Formulation, From 2021 to 2026 (USD Million)
  30. Italy Injectable Drug Delivery Market, By Therapeutic Use, From 2021 to 2026 (USD Million)
  31. Italy Injectable Drug Delivery Market, By End-user, From 2021 to 2026 (USD Million)
  32. Spain Injectable Drug Delivery Market, By Device Type , From 2021 to 2026 (USD Million)
  33. Spain Injectable Drug Delivery Market, By Formulation, From 2021 to 2026 (USD Million)
  34. Spain Injectable Drug Delivery Market, By Therapeutic Use, From 2021 to 2026 (USD Million)
  35. Spain Injectable Drug Delivery Market, By End-user, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample